New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 6.25mg;   - tablet - 6.25 mg - active: carvedilol 6.25mg   excipient: colloidal silicon dioxide crospovidone iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - entecavir monohydrate 0.532mg equivalent to 0.5 mg entecavir - film coated tablet - 0.5 mg - active: entecavir monohydrate 0.532mg equivalent to 0.5 mg entecavir excipient: crospovidone hypromellose lactose monohydrate macrogol 6000 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - entecavir sandoz is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag negative chronic hbv infection with compensated liver disease.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - entecavir monohydrate 1.065mg equivalent to 1.0 mg entecavir - film coated tablet - 1 mg - active: entecavir monohydrate 1.065mg equivalent to 1.0 mg entecavir excipient: crospovidone hypromellose iron oxide red iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - entecavir sandoz is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag negative chronic hbv infection with compensated liver disease.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 10mg;   - modified release tablet - 10 mg - active: oxycodone hydrochloride 10mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil glycerol(mono,tri)docosanoat [behenoyl polyoxyglyerides] lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 20mg;   - modified release tablet - 20 mg - active: oxycodone hydrochloride 20mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil glycerol(mono,tri)docosanoat [behenoyl polyoxyglycerides] iron oxide red lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 40mg;   - modified release tablet - 40 mg - active: oxycodone hydrochloride 40mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil glycerol(mono,tri)docosanoat [behenoyl polyoxyglycerides] iron oxide yellow lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 5mg;   - modified release tablet - 5 mg - active: oxycodone hydrochloride 5mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil indigo carmine glycerol(mono,tri)docosanoat [behenoyl polyoxyglyerides] lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - oxycodone hydrochloride 80mg;   - modified release tablet - 80 mg - active: oxycodone hydrochloride 80mg   excipient: colloidal silicon dioxide copovidone hydrogenated castor oil glycerol(mono,tri)docosanoat [behenoyl polyoxyglycerides] green lake - mixture of quinoline yellow (e104) and indigo carmine (e132) iron oxide black lactose monohydrate magnesium stearate maize starch medium-chain triglycerides sepifilm white lp761 - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tadalafil 10mg - film coated tablet - 10 mg - active: tadalafil 10mg excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 32k520017 sorbitan stearate - tadalafil sandoz is indicated for the treatment of: · erectile dysfunction (ed) in adult men. in order for tadalafil sandoz to be effective in treating ed, sexual stimulation is required. · moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult men · adult men with co-existing ed and luts associated with bph.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tadalafil 20mg - film coated tablet - 20 mg - active: tadalafil 20mg excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 32k520009 sorbitan stearate - tadalafil sandoz is indicated for the treatment of: · erectile dysfunction (ed) in adult men. in order for tadalafil sandoz to be effective in treating ed, sexual stimulation is required. · moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult men · adult men with co-existing ed and luts associated with bph.